text: FDA backs new multiple sclerosis drug The Food and Drug Administration strongly endorsed Biogen Idec Inc.'s new multiple sclerosis treatment, putting the Cambridge firm in position to expand the market for MS drugs and win greater market share. The drug, formerly called Antegren but renamed Tysabri, was developed with Elan Pharmaceuticals of Ireland. The FDA approved Tysabri for use on its own and in ...